Study identification

PURI

https://redirect.ema.europa.eu/resource/18587

EU PAS number

EUPAS17954

Study ID

18587

Official title and acronym

A cohort study with a nested case control analysis on the association between acid-suppressing drugs and seizures using THIN database in the UK (Acid suppressing Drug Seizure Epidemiology Study)

DARWIN EU® study

No

Study countries

Spain

Study description

In this observational study (NCT01744301), patients aged 20–84 years in 2005–2011 were identified from The Health Improvement Network. The relative risk of seizure associated with use of proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) in a general population was quantified, overall and stratified by epilepsy status, and the effects of demographics and comorbidities were determined. In a nested case–control analysis, seizure cases were matched to controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using unconditional logistic regression. Estimates were adjusted for potential confounders.

Study status

Finalised
Research institution and networks

Institutions

Contact details

Luis Alberto García Rodríguez

Primary lead investigator
Study timelines

Date when funding contract was signed

Actual:

Study start date

Actual:

Data analysis start date

Actual:

Date of final study report

Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

AstraZeneca
Study protocol
Initial protocol
English (362.79 KB - PDF)View document
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)